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Introduction CYP27B1 is the mitochondrial cytochrome P450 that catalyzes the final step of vitamin D activation, the 1α-hydroxylation of 25-hydroxyvitamin D3 (25(OH)D3) to give 1,25-dihydroxyvitamin D3 (1,25(OH) 2 D3). 1,25(OH) 2 D3 maintains calcium and phosphorus homeostasis and also plays an important role in regulating the immune system and displays antiproliferative and prodifferentiative properties on many different cell-types (Prosser and Jones, 2004; Bouillon et al., 2006; Masuda and Jones, 2006; Takahashi and Morikawa, 2006; Holick, 2007; Bikle, 2009) . Its potential for the treatment of cancer and immune disorders is however limited, due largely to the toxic hypercalcemia that occurs at the supraphysiological doses required. This has led to the search for new vitamin D analogs that retain the antiproliferative and prodifferentiative properties of 1,25(OH) 2 D3 but are not calcemic (Masuda and Jones, 2006; Takahashi and Morikawa, 2006; Lee et al., 2008; Slominski et al., 2010) .
Vitamin D analogs that have such properties are produced by the action of cytochrome P450scc (CYP11A1) on vitamin D Slominski et al., 2011; Wang et al., 2012) , and several of them show anti-melanoma activity in cell culture models Slominski et al., 2012a; Slominski et al., 2013b) . CYP11A1 can act on vitamin D3 producing at least 8 different mono-, di-and tri-hydroxyvitamin D derivatives, with the major products being 20S-hydroxyvitamin D3 (20(OH)D3) and 20, 23(OH) 2 D3) ( Fig. 1) (Guryev et al., 2003; Slominski et al., 2005; Tuckey et al., 2008a; Tuckey et al., 2011; Slominski et al., 2012b) . Several of these secosteroids appear to be produced in vivo, with 20(OH)D3, 22(OH)D3, 20,23(OH) 2 D3 and 17,20,23(OH) 3 D3 being detected in cultured keratinocytes without the addition of exogenous vitamin D3 as a substrate (Slominski et al., 2012b) . To date, 20(OH)D3 and 20,23(OH) 2 D3, as well as 20-hydroxyvitamin D2 (20(OH)D2), the major product of CYP11A1 activity on vitamin D2 (Slominski et al., 2006; Nguyen et al., 2009) , are the most extensively studied for their biological effects. Via binding to the vitamin D receptor (VDR), these compounds can inhibit keratinocyte, melanoma, leukemia, DMD #50955 breast and liver cancer cell proliferation, promote differentiation, and display anti-inflammatory activity by decreasing nuclear factor-ĸB activity (Zbytek et al., 2008; Janjetovic et al., 2009; Janjetovic et al., 2010; Li et al., 2010; Slominski et al., 2010; Tang et al., 2010a; Janjetovic et al., 2011; Slominski et al., 2011; Tuckey et al., 2011; Kim et al., 2012; Lu et al., 2012; Slominski et al., 2012a; Wang et al., 2012) . Importantly, all three of these derivatives lack calcemic activity in rodents, even at relatively high doses Wang et al., 2012; Slominski et al., 2013a) . However, the addition of a hydroxyl group to 20(OH)D3 at the 1α-position (producing 1α,20-dihydroxyvitamin D3, 1,20(OH) 2 D3) causes the appearance of some calcemic activity, although less than that for 1,25(OH) 2 D3 . The therapeutic potential of the non-calcemic, CYP11A1-derived secosteroids is illustrated by the marked reduction in collagen synthesis and clinical signs of bleomycin-induced scleroderma in mice seen following 20(OH)D3 treatment (Slominski et al., 2013a) .
Recently we have shown that 20(OH)D3 can be hydroxylated by cytochromes P450 that are involved in the preliminary activation (25-hydroxylase, CYP27A1) and inactivation (24-hydroxylase, CYP24A1) of vitamin D3 (Tieu et al., 2011; Tieu et al., 2012) . Specifically, CYP27A1 hydroxylates 20(OH)D3 at either C25 or C26, producing 20, 25(OH) 2 D3) and 20,26-dihydroxyvitamin D3 (20,26(OH) 2 D3) (Tieu et al., 2011) . CYP24A1 also hydroxylates 20(OH)D3 at C25 producing 20,25(OH) 2 D3. Additionally, it hydroxylates at the expected C24 position producing 20,24-dihydroxyvitamin D3 (20,24(OH) 2 D3) ( Fig. 1) . All three of these products, are more potent than the parent, 20(OH)D3, at inhibiting colony-formation by melanoma cells in soft agar ).
Previously we reported that purified mouse CYP27B1 can 1α-hydroxylate the two major products of CYP11A1 action on vitamin D3, 20(OH)D3 and 20,23(OH) 2 D3, and one of the major products of CYP11A1 action on vitamin D2, 20(OH)D2, with the products displaying altered biological activity compared to the parent secosteroids (Tang et al., 2010a; Tang et al., 2010b; Slominski et al., 2011; DMD #50955 6 Tang et al., 2012) . Recently we successfully expressed human CYP27B1 in Escherichia coli (E. coli), extracted and partially-purified the enzyme, and carried out a detailed characterization of its catalytic activity on its classical substrates . To further characterize CYP27B1, especially the human isoform, and to further characterize the ability the CYP11A1-derived secosteroids to be metabolized by cytochromes P450, we examined the ability of both human and mouse CYP27B1 to metabolize these secosteroids, including those further hydroxylated by CYP27A1 and CYP24A1 (Fig.   1 ).

Materials and Methods
Preparation of enzymes and vitamin D analogs. Mouse and human adrenodoxin and human adrenodoxin reductase were expressed in E. coli and purified as before (Woods et al., 1998; Tuckey and Sadleir, 1999; Tang et al., 2010b; Tang et al., 2012) . Mouse and human CYP27B1 were coexpressed in E. coli with the chaperonins, GroEL/ES, to facilitate correct protein-folding as described before (Tang et al., 2010b; Tang et al., 2012) . The cDNA constructs for mouse and human CYP27B1 encoded a 4-and 6-histidine tag, respectively, at the C-terminus, and the N-terminal mitochondrialtargeting sequences were removed. The expressed mouse and human CYP27B1 were extracted using CHAPS detergent and purified by nickel affinity-and octyl Sepharose-chromatography (Tang et al., 2010b; Tang et al., 2012) . (17,20,23(OH) 3 D3) were generated by the action of CYP11A1 on vitamin D3 solubilized in 2-hydroxypropyl-β-cyclodextrin and purified by thin layer chromatography and HPLC (Guryev et al., 2003; Tuckey et al., 2008a; Tuckey et al., 2011) . 20,24(OH) 2 D3 and 20,25(H) 2 D3 were produced by the action of rat CYP24A1 on 20(OH)D3 while 20,26(OH) 2 D3 was generated by the action of human CYP27A1 on 20(OH)D3 (Tieu et al., 2011) .
Measurement of human CYP27B1 activity in phospholipid vesicles. Phospholipid vesicles
comprising DOPC (Sigma-Aldrich from St. Louis, MO, U.S.A), bovine heart cardiolipin (SigmaAldrich from St. Louis, MO, U.S.A.) and the vitamin D3 analogs under study were prepared by sonication in a bath-type sonicator as described in detail before (Lambeth et al., 1982; Tuckey and Kamin, 1982; Tuckey et al., 2008b) . The incubation mixture comprised vesicles (510 μM phospholipid), CYP27B1 (5-800 nM), adrenodoxin (15 μM), adrenodoxin reductase (0.4 μM), glucose 6-phosphate (2 mM), glucose-6-phosphate dehydrogenase (2 U/ml) and NADPH (50 μM), in the same DMD #50955 8 buffer used for vesicle preparation (20 mM HEPES pH 7.4, 100 mM NaCl, 0.1 mM DTT, 0.1 mM EDTA). Samples (typically 0.25-2.0 ml) were preincubated for 4 min at 37°C and then the reaction was initiated by the addition of adrenodoxin. Samples were incubated at 37°C with shaking for 2 min (unless otherwise stated) and then reactions were terminated by the addition of 2-volumes of ice-cold dichloromethane and vortexing (Guryev et al., 2003) . After phase separation by centrifugation, the lower organic phase was retained, and the upper aqueous phase was extracted twice more with two volumes of dichloromethane. The dichloromethane was subsequently removed under nitrogen and the residual sample was dissolved in 64% or 75% methanol in water or 100% ethanol for analysis. Product formation was measured by reverse-phase HPLC using either a Perkin Elmer (Biocompatible Binary Pump 250)/ TurboChrom or HP Agilent 1050/ ChemStation system with a GraceSmart C18 column (4.6 × 150 mm, particle size 5 µm) as described before (Tang et al., 2010b) .
Analysis of kinetics data. The experimental data were fitted to the Michaelis-Menten equation.
If substrate inhibition was observed, data were also fitted to the inhibition model equation that has been described by us before (Tang et al., 2010b) , using Kaleidagraph 4.1 (Abelbeck Synergy Software from Reading, PA, U.S.A.). This equation is derived from a model where two molecules of substrate bind to the enzyme substrate complex simultaneously with equal K i values to form an ES3 complex that is catalytically inactive. As well as the K m and k cat values, this equation also provides the inhibitor constant for substrate (K i ).
Large-scale preparation of 1α-hydroxylated metabolites. To produce metabolites on a scale that permitted structure determination by NMR (more than 30 µg), mouse CYP27B1 (0.3 μM) was incubated with 20,24(OH) 2 D3, 20,25(OH) 2 D3 or 20,26(OH) 2 D3 incorporated into phospholipid vesicles (0.025 or 0.03 mol/mol phospholipid) in 10-25 mL incubations comprising vesicle preparation buffer (see above), 15 μM mouse adrenodoxin, 0.4 μM human adrenodoxin reductase, 2 mM glucose-6-phosphate, 2 U/mL glucose-6-phosphate dehydrogenase and 50 μM NADPH. The reactions were DMD #50955 performed for 1 h at 25°C with shaking. Reactions were stopped with two volumes of ice-cold dichloromethane and products were extracted in a scaled-up version of that described above. The products were purified by reverse-phase HPLC using a GraceSmart column (Perkin Elmer Biocompatible Binary Pump / TurboChrom system) with a gradient of 64% methanol in water at a flow rate of 0.5 mL/min for 10 min (Guryev et al., 2003; Tuckey et al., 2008a) . The yield of products, subsequently shown to be the expected 1,20,24(OH) 3 D3, 1,20,25(OH) 3 D3 and 1,20,26(OH) 3 D3 (see Results) was determined spectrophotometrically at 263 nm using an extinction coefficient of 18,000 M -1 cm -1 (Hiwatashi et al., 1982) . Measurement of cell proliferation in soft agar. The effect of the secosteroids hydroxylated by CYP27B1 on the tumorigenicity of SKMEL-188 melanoma cells was determined by assaying their ability to form colonies in soft agar, as described in detail before (Slominski et al., 2012a; Tieu et al., 2012 ). Secosteroids were added in 100 µL media to final concentrations of 0.1 nM or 10 nM. Each condition was tested in quadruplicates. Cells were grown at 37°C with 5% CO 2 over two weeks, with secosteroids in fresh media (100 µL) being added after every 72 h. Colonies were then scored and stained with MTT (methylthiazol-tetrazolium) reagent (Promega from Madison, WI, U.S.A.), and then counted under the microscope. Data were analyzed with Student's t test (for two groups) using Prism 4.0 (GraphPad Software from San Diego, CA, U.S.A.).
Other procedures. The concentration of CYP27B1 was determined from the CO-reduced minus reduced difference spectrum using an extinction coefficient of 91,000 M -1 cm -1 for the absorbance difference between 450 and 490 nm (Omura and Sato, 1964) . The concentrations of all hydroxyvitamin D3 stock solutions were determined using an extinction coefficient of 18,000 M -1 cm -1 at 263 nm (Hiwatashi et al., 1982) . 
Results
Kinetics of the metabolism of CYP11A1-derived vitamin D3 analogs by CYP27B1.
CYP27B1 activity was measured with substrates incorporated into phospholipid vesicles, a system that mimics the native environment of the cytochrome in the inner mitochondrial membrane, which we have employed previously with CYP27B1 (Tang et al., 2010b; Tang et al., 2012) where limited substrate was available and the hydroxylation rate was low, insufficient product was generated by CYP27B1 to identify their structures by NMR but it is presumed that they are the 1α-hydroxy derivatives. For all substrates where the metabolite was identified, there was a single 1α-hydroxylated product with both the mouse and human enzymes. This is illustrated in Fig. 2 (Fig. 2D) indicating that the presence of the 17α-hydroxyl group prevented hydroxylation by CYP27B1. This was also the case for the metabolism of 17,20(OH) 2 D2 by CYP27B1 where in contrast to 20(OH)D2 (Tang et al., 2010b) , no hydroxylation was observed (data not shown).
We have previously reported that inhibition of both mouse and human CYP27B1 occurs with high concentrations of 25(OH)D3 (Tang et al., 2010b; Tang et al., 2012 ). In the current study, no inhibition of mouse or human CYP27B1 activity was observed at high concentrations of 20(OH)D3 or 20,23(OH) 2 D3, but weak substrate inhibition was observed for 20,26(OH) 2 D3 (as shown in Fig. 3 for the human enzyme) giving a K i value of 133 mmol/mol phospholipid which is 30 times higher than its K m . High concentrations of 20,24(OH) 2 D3 inhibited the mouse enzyme, giving a K i value of 241 mmol/mol phospholipid, which is 166-fold higher than its K m . 20,22(OH) 2 D3 also showed substrate inhibition with mouse CYP27B1 (K i = 37.4 mmol/mol phospholipid), but due to low activity, kinetic parameters were not measured for the human enzyme. In each case where inhibition was observed, the data fitted well to a one catalytic site-two inhibitory site-model (see Materials and Methods). Since the K i values were very high relative to the K m values and the K m and k cat values calculated from a Michaelis-Menten curve fit (using data at lower substrate concentrations) were indistinguishable from those determined with the inhibition model, only the Michaelis-Menten data are shown (Table 1) . 20(OH)D3 was metabolized relatively poorly by human and mouse CYP27B1, displaying higher K m and lower k cat values than for 25(OH)D3. 22(OH)D3 was an even poorer substrate for both mouse and human CYP27B1, as shown in a 1 h incubation of mouse CYP27B1 with this secosteroid compared to 20(OH)D3 (Fig. 4) . The low activity with 22(OH)D3 and the limited amount of this secosteroid available prevented a full kinetic analysis from being carried out.
When the vitamin D3 side chain contained both 20-and 22-hydroxyl groups (as in 20,22(OH) 2 D3), activity was also low with the k cat being 5-fold lower than that for 20(OH)D3 for the mouse enzyme, and too low to quantitate for the human enzyme. Movement of the second hydroxyl (Table 1 ). This could be due to very poor binding of the analogs to the active site of CYP27B1, or binding in a position that prevents hydroxylation. To distinguish between these possibilities we tested the ability of 17,20(OH) 2 D3 to inhibit the 1α-hydroxylation of 25(OH)D3.
Significant inhibition of human CYP27B1 activity was seen at ratios of 17,20(OH) 2 D3:25(OH)D3 of 0.5:1, 1:1 and 2:1 but no inhibition was observed for the mouse enzyme at these ratios ( (Fig. 9B) . H coupling constants between protons attached to C1 and C2, as described in the following text using 1,20,26(OH) 3 D3 as an example. Firstly, the proton chemical shift (4.35 ppm) at C1 (Fig. 10) is very similar to that of the 1β-H (4.29 ppm) in 1,25(OH) 2 D3 measured in the same solvent (CD 3 OD) (Eguchi and Ikekawa, 1990) . Secondly, the vicinal 1 DMD #50955 H-2β = 5.9 Hz) between the proton at C1 and the two protons at C2 of this metabolite is essentially the same with that in 1,25(OH) 2 D3 ( 3 J H-1β, H-2α = 3 J H-1β, H-2β = 6.0) (Eguchi and Ikekawa, 1990 ). This pseudotriplet splitting pattern is only possible when the proton directly attached to C1 is in the 1β-configuration due to similar vicinal coupling constants between H-1β and H-2α ( must be in the 1α-configuration for all three CYP27B1-derived products.
The effect of 1α-hydroxylation on anti-melanoma activity. Targeting of the VDR represents a promising strategy for treatment of melanoma (Pinczewski and Slominski, 2010; Brozyna et al., 2011; Szyszka et al., 2012 ), a deadly disease for which therapy is still unsatisfactory (Hauschild et al., 2012 ).
Therefore, we tested whether the 1α-hydroxylation of 20,25(OH) 2 D3 and 20,26(OH) 2 D3, both good substrates for CYP27B1, altered their ability to inhibit melanoma colony formation in soft agar. This assay was previously used to characterize the parent compounds and is a good measure of tumorigenicity. While 20,24(OH) 2 D3 is also an excellent substrate for CYP27B1, this had not been synthesized at the time of testing.
The parent compounds and their 1α-hydroxy derivatives at 10 nM significantly inhibited colony formation compared to the vehicle control (p<0.0002). Excluding 1,20,26(OH) 3 D3, they also inhibited colony formation significantly more than 20(OH)D3 . These significant differences were also seen when the secosteroid concentration was decreased to 0.1 nM (Fig. 11) 
Discussion
The ability of CYP11A1 to hydroxylate the vitamin D3 side chain at C20 and C22 has enabled us to look at the effect of the position of the side chain hydroxyl group on CYP27B1 activity. The current study shows that when the hydroxyl group on the vitamin D side chain is moved from C25 to C20, the catalytic efficiency (k cat /K m ) of the 1α-hydroxylase decreases by 40-to 45-fold, due to both an increase in K m and decrease in k cat . When the side chain hydroxyl group is at C22, rather than at C20, the activity is even lower not permitting measurement of its kinetic parameters.
Recently we reported that 20(OH)D3 can be hydroxylated by two vitamin D metabolising enzymes, human CYP27A1 (Tieu et al., 2011) and rat CYP24A1 containing a 20-hydroxyl group plus one addition hydroxyl group at every position on the side chain, except C21 (note that C26 and C27 are equivalent). All of these 20-hydroxy derivatives have been shown to be biologically active (Zbytek et al., 2008; Janjetovic et al., 2009; Janjetovic et al., 2010; Slominski et al., 2010; Tang et al., 2010a; Janjetovic et al., 2011; Slominski et al., 2011; Tuckey et al., 2011; Kim et al., 2012; Lu et al., 2012; Slominski et al., 2012a; Wang et al., 2012) high CYP27B1 concentrations. The ability of the 17α-hydroxyl group to completely inhibit CYP27B1 activity was also seen with the trihydroxy derivative, 17,20,23(OH) 3 D3, and the vitamin D2 derivative, 17,20(OH) 2 D2. We observed that 17,20(OH) 2 D3 could inhibit 25(OH)D3 metabolism by human CYP27B1, but not the mouse enzyme, suggesting that it can bind to the active site of the human enzyme, but in an orientation that precludes hydroxylation.
Overall, the kinetic data presented in this study indicate that the position of one or more hydroxyl groups on the vitamin D side chain dramatically influences the ability of both mouse and human CYP27B1 to hydroxylate the derivative. Yamamoto and co-workers (Yamamoto et al., 2004; Yamamoto et al., 2005 ) prepared a modelled structure of CYP27B1 and used mutagenesis to conclude that Thr409 of the human CYP27B1 hydrogen bonds to the 25-hydroxyl group of 25(OH)D3, playing a critical role in substrate binding. Since we observed that the K m values for 20,24(OH) 2 D3, 20,25(OH) 2 D3 and 20,26(OH) 2 D3 were comparable to, or lower than for 25(OH)D3, it would seem likely that a hydroxyl group at C24 or C26, like at C25, can also hydrogen bond to Thr409. The higher K m values observed with 20(OH)D3 and 20,22(OH) 2 D3 suggests that their side chain hydroxyl groups are too far from Thr409 to form this hydrogen bond. Differences in the observed k cat values between different substrates are likely due to the distance of C1 from the activated oxygen bound to the heme group, or steric effects of the substrate on the optimal conformation of the enzyme for catalysis.
The present work shows that the position and number of hydroxyl groups on the side chain of the vitamin D analog does not alter the site of hydroxylation by CYP27B1, which is always the C1α-position. This suggests that the A ring of vitamin D analogs must bind to the enzyme active site in a specific orientation so that only the 1α-hydroxy derivative is produced. Thus, CYP27B1 is highly specific for 1α-hydroxylation, consistent with the limited literature available where there are no reports for this enzyme hydroxylating at the C1β-position or at adjacent carbon atoms. However, low 25-hydroxylase activity of CYP27B1 has been observed when 1α-hydroxyvitamin D3 is used as substrate requiring binding of the secosteroid into the active site of the enzyme in the opposite orientation to that for 1α-hydroxylation (Uchida et al., 2004; Tang et al., 2010b) .
It has been documented that the CYP11A1-derived vitamin D3 analogs, 20(OH)D3 and 20,23(OH) 2 D3, display similar properties to 1,25(OH) 2 D3 such as inhibiting cell proliferation, promoting differentiation of keratinocytes and leukemia cells, and suppressing tumorigenicity of melanoma (Zbytek et al., 2008; Janjetovic et al., 2009; Li et al., 2010; Slominski et al., 2010; Janjetovic et al., 2011; Tuckey et al., 2011; Kim et al., 2012; Lu et al., 2012; Slominski et al., 2012a; Wang et al., 2012) . Importantly in terms of their potential for therapeutic applications such as in the treatment of scleroderma (Slominski et al., 2013a) , it has been shown that unlike 1,25(OH) 2 D3, 20(OH)D3 lacks calcemic activity in rodents at a dose of up to 30 μg/kg, whereas severe hypercalcemia was detected with 1,25(OH) 2 D3 at a dose of only 2 μg/kg . However, when a 1α-hydroxyl group was added to 20(OH)D3 to produce 1,20(OH) 2 D3, moderate calcemic activity was observed . This suggests that the presence of a 1α-hydroxyl group is necessary for the vitamin D analog to regulate serum calcium levels. Thus, the relatively poor ability of CYP27B1 to hydroxylate CYP11A1-derived hydroxyvitamin D3 analogs may be important in vivo for preventing them from causing hypercalcemia. It has to be noted that both 20(OH)D3 and 20(OH)D2 do not require hydroxylation to express phenotypic activity . Nevertheless, there is evidence for at least some 1α-hydroxylation of 20(OH)D3 and 20,23(OH) 2 D3 in vivo as their 1α-hydroxylated products have been detected in placental explants incubated with vitamin D3 and in cultured keratinocytes (Slominski et al., 2012b) . The CYP11A1-derived secosteroids, 17,20(OH) 2 D2, 17,20(OH) 2 D3 and 17, 20, 23(OH) In this study, we performed an initial investigation of the anti-proliferative activity of two of the new trihydroxy derivatives generated with high catalytic efficiency by CYP27B1, 1,20,25(OH) 3 D3 and 1,20,26(OH) 3 D3, and compared this to the activity of their parent secosteroids, 20,25(OH) 2 D3 and 20,26(OH) 2 D3. As reported before , the parent secosteroids displayed significantly higher inhibitory effect on colony formation by melanoma cells grown in soft agar than either 20(OH)D3 or 1,25(OH) 2 D3 at concentrations of both 0.1 nM and 10 nM. Interestingly, the antiproliferative activity of 1,20,25(OH) 3 D3 and 1,20,26(OH) 3 D3 on melanoma cells (SKMEL-188) was found to be significantly different to that of their parent compounds, with a greater effect seen for 1,20,25(OH) 3 D3, and a lesser effect for 1,20,26(OH) 3 D3 (although still significantly more than for 20(OH)D3). The increased potency resulting from the 1α-hydroxylation of 20,25(OH) 2 D3, with the product completely inhibiting colony formation at 10 nM and inhibiting by 66% at 0.1 nM, suggests that it is a good candidate for further testing of its anti-melanoma activity. The above data is also consistent with recent clinico-pathological analyses that clearly demonstrate a decrease in CYP27B1 expression during progression of melanoma, as well as with the positive correlation between shorter survival of patients and low CYP27B1 expression in melanoma specimens (Brożyna et al., 2012) . Thus, the current and the previous study suggest that CYP27A1 and CYP24A1 can increase the antimelanoma potency of 20(OH)D3, with further modification by CYP27B1. Based on our previous studies (Kim et al., 2012; Slominski et al., 2012a) , we expect that these effects are mediated through the activation of the vitamin D receptor. However, the final proof would require additional testing using models described previously (Kim et al., 2012) , and an extended panel of melanoma lines available in our laboratories, and comparison to normal melanocytes (Brożyna et al., 2012; Slominski et al., 2012a; Slominski et al., 2013a; Slominski et al., 2013b ). This will be complemented by testing the toxicity of these modified compounds. In conclusion, this study clearly defines the kinetic parameters for the action of CYP27B1 on a range of secosteroids produced by CYP11A1, in a vesicle-reconstituted system that resembles the inner mitochondrial membrane. All the secosteroids produced directly by CYP11A1 action on vitamin D3 are relatively poor substrates for CYP27B1. In contrast, the secondary metabolites produced by the action of CYP27A1 or CYP24A1 on 20(OH)D3, which have a hydroxyl group close to the end of the side chain, are very good substrates for CYP27B1. human CYP27B1was incubated with 25(OH)D3 at a concentration of 0.025 mol/mol phospholipid in vesicles for 2 min with 17,20(OH) 2 D3 present at the ratios indicated. Data represent means ± SEM (n=3), and they were analyzed using the Student's t test on GraphPad Prism. Statistical significance: *, p < 0.05, ** p < 0.01, *** p < 0.001. cells. Colony formation was determined using the soft agar assay and colonies of greater than 0.2 mm were counted. Data represent means ± SEM (n=4), and they were analyzed using the Student's t test on GraphPad Prism. Statistical significance: *, p < 0.05, ** p < 0.01, *** p < 0.001.
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